扁桃体来源间充质干细胞对特应性皮炎模型小鼠的治疗作用。
Therapeutic Effects of Tonsil-derived Mesenchymal Stem Cells in an Atopic Dermatitis Mouse Model.
机构信息
Institute of New Frontier Research Team, Hallym University, Hallym Clinical and Translation Science Institute, Chuncheon, Republic of Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Republic of Korea.
出版信息
In Vivo. 2021 Mar-Apr;35(2):845-857. doi: 10.21873/invivo.12325.
BACKGROUND/AIM: Mesenchymal stem cells (MSCs) have been suggested as an alternative therapeutic option in atopic dermatitis. Palatine tonsils are lymphoepithelial tissue located around the oropharynx and have been proposed as one of the important alternative sources of MSCs. The purpose of this study was to evaluate the protective and therapeutic effects of tonsil-derived MSCs (TMSCs) in a 2,4-dinitrofluorobenzene (DNFB)-induced mouse model of atopic dermatitis (AD).
MATERIALS AND METHODS
The effect of TMSCs was evaluated in 20 C57BL/6J mice that were randomly divided into four groups (normal, DNFB-PBS, DNFB-TMSC7, and DNFB-TMSC16 group). TMSCs were subcutaneously injected into DNFB-sensitized mice on day 7 (DNFB-TMSC7 group) and day 16 (DNFB-TMSC16 group). Several parameters of inflammation were assessed.
RESULTS
Subcutaneously injected TMSCs significantly improved the inflammatory symptoms in a DNFB-induced AD model mice, particularly showing therapeutic effects rather than protective effects. TMSC treatment inhibited T-cell-mediated inflammatory responses by decreasing the levels of IL-6, IL-1β, TNF-α (Th1 cell marker), IL-4 (Th2 cell marker), and B-cell-mediated serum IgE. In contrast, TMSCs enhanced the anti-inflammatory cytokine TGF-β.
CONCLUSION
In vitro and in vivo results suggest that TMSC treatment improved inflammatory skin lesions in the DNFB-induced AD mice model via immunomodulatory effects of the TMSCs. TMSCs inhibit T-cell and B-cell mediated responses, and enhance the anti-inflammatory responses.
背景/目的：间充质干细胞（MSCs）已被提议作为特应性皮炎的一种替代治疗选择。扁桃体是位于口咽周围的淋巴上皮组织，被认为是 MSC 的重要替代来源之一。本研究的目的是评估扁桃体来源的间充质干细胞（TMSCs）在 2,4-二硝基氟苯（DNFB）诱导的特应性皮炎（AD）小鼠模型中的保护和治疗作用。
材料和方法
将 20 只 C57BL/6J 小鼠随机分为四组（正常组、DNFB-PBS 组、DNFB-TMSC7 组和 DNFB-TMSC16 组），评估 TMSCs 的作用。在第 7 天（DNFB-TMSC7 组）和第 16 天（DNFB-TMSC16 组），将 TMSCs 皮下注射到 DNFB 致敏的小鼠中。评估了几种炎症参数。
结果
皮下注射 TMSCs 可显著改善 DNFB 诱导的 AD 模型小鼠的炎症症状，特别是表现出治疗作用而不是保护作用。TMSC 治疗通过降低 IL-6、IL-1β、TNF-α（Th1 细胞标记物）、IL-4（Th2 细胞标记物）和 B 细胞介导的血清 IgE 的水平，抑制 T 细胞介导的炎症反应。相反，TMSCs 增强了抗炎细胞因子 TGF-β。
结论
体内外结果表明，TMSC 治疗通过 TMSC 的免疫调节作用改善了 DNFB 诱导的 AD 小鼠模型中的炎症皮肤损伤。TMSCs 抑制 T 细胞和 B 细胞介导的反应，并增强抗炎反应。
Zotero 插件